Page last updated: 2024-11-04

pheniprazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pheniprazine: was heading 1963-94; use HYDRAZINES to search PHENIPRAZINE 1966-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5929
CHEMBL ID22498
CHEBI ID134773
SCHEMBL ID163709
MeSH IDM0225168

Synonyms (47)

Synonym
pheniprazine
hydrazine, 1-methyl-2-phenylethyl
NCIOPEN2_000669
dicatron
feniprazina [inn-spanish]
pheniprazine [inn:ban]
2-hydrazino-1-phenylpropane
hydrazine, (1-methyl-2-phenylethyl)-
einecs 200-236-6
feniprazyne [polish]
beta-phenylisopropylhydrazine
fenilisopropilidrazina
2-hydrazinopropylbenzene
1-phenyl-2-hydrazinopropane
pheniprazinum [inn-latin]
(alpha-methylphenethyl)hydrazine
p 1142
catron
hydrazine, (alpha-methylphenethyl)-
phenizine
CHEBI:134773
pheniprazine dl-form
CHEMBL22498
55-52-7
1-phenylpropan-2-ylhydrazine
feniprazina
pheniprazinum
unii-37vkd7067m
37vkd7067m ,
feniprazyne
SCHEMBL163709
pheniprazine dl-form [mi]
pheniprazine [inn]
52031-11-5
pheniprazine [who-dd]
DTXSID6043838
VXTWEDPZMSVFEF-UHFFFAOYSA-N
DB09250
AKOS026733800
1-(1-methyl-2-phenylethyl)hydrazine
sr-01000944902
SR-01000944902-1
Q7181347
CS-0286846
HY-W224327
(1-phenylpropan-2-yl)hydrazine
EN300-274949

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990113 (96.58)18.7374
1990's1 (0.85)18.2507
2000's2 (1.71)29.6817
2010's1 (0.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.15 (24.57)
Research Supply Index4.81 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (97.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]